Skip to content
Boost Up Blog – Lifestyle
Author:
China Medical System Holdings Ltd.
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
November 4, 2026
CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
September 9, 2026
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
September 3, 2026
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
June 22, 2026
CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
June 8, 2026